Management of hyperlipidaemia

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Hyperlipidaemia, characterized by elevated plasma lipids, is a significant risk factor for coronary heart disease (CHD).
• Cholesterol-lowering medications, primarily statins, represent a substantial and growing portion of Australia's pharmaceutical expenditure.
• Primary hypercholesterolaemia warrants focused attention due to its link with cardiovascular disease.

Purpose of the Study:

• To examine the relationship between primary hypercholesterolaemia and coronary heart disease (CHD).
• To review the management of hypercholesterolaemia in community settings.
• To evaluate the efficacy and safety of statin therapy.

Main Methods:

• Review of existing evidence on statin therapy for hypercholesterolaemia and CHD.
• Analysis of treatment benefits across different patient demographics and risk profiles.
• Assessment of drug discontinuation rates and adverse event occurrences.

Main Results:

• Strong evidence supports statin use in middle-aged men with established CHD, reducing mortality and morbidity.
• Weaker but reasonable evidence supports statin use in older men, women with CHD, and high-risk individuals without diagnosed CHD.
• Potential benefits extend to patients with stroke and peripheral vascular disease at risk for CHD.

Conclusions:

• Statin therapy offers significant benefits for specific patient groups at risk of or with established cardiovascular disease.
• While discontinuation rates are notable, serious adverse reactions to statins are infrequent.
• Management strategies should consider individual patient risk and potential benefits of lipid-lowering therapy.